Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2018

Open Access 01-04-2018 | Original article

Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study

Published in: Clinical and Experimental Nephrology | Issue 2/2018

Login to get access

Abstract

Background

Because of the necessity for extended period and large costs until the event occurs, surrogate endpoints are indispensable for implementation of clinical studies to improve chronic kidney disease (CKD) patients’ prognosis.

Methods

Subjects with serum creatinine level for a baseline period over 1–3 years were enrolled (n = 69,238) in this community-based prospective cohort study in Okinawa, Japan, and followed up for 15 years. The endpoint was end-stage renal disease (ESRD). The percent of estimated glomerular filtration rate (%eGFR) change was calculated on the basis of the baseline period.

Results

Subjects had a mean ± SD age, 55.59 ± 14.69 years; eGFR, 80.15 ± 21.15 ml/min/1.73 m2. Among the subjects recruited, 15.81% had a low eGFR (<60 ml/min/1.73 m2) and 36.1/100,000 person years developed ESRD. Cox proportional hazards models adjusted for baseline characteristics showed that the risk of ESRD tended to be high with high rates of decrease in %eGFR changes over 2 or 3 years in the high- and low-eGFR groups. The specificities and positive predictive values for ESRD based on a cutoff value of %eGFR change of less than −30% over 2 or 3 years were high in the high- and low-eGFR groups.

Conclusions

%eGFR change tends to be associated with the risk of ESRD. %eGFR change of less than −30% over 2 or 3 years can be a candidate surrogate endpoint for ESRD in the general Japanese population.
Literature
1.
go back to reference Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.CrossRef Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.CrossRef
2.
go back to reference Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31.CrossRefPubMedPubMedCentral Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31.CrossRefPubMedPubMedCentral
3.
go back to reference Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64:848–59.CrossRefPubMed Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64:848–59.CrossRefPubMed
4.
go back to reference Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis. 2014;64:860–6.CrossRefPubMed Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis. 2014;64:860–6.CrossRefPubMed
5.
go back to reference Greene T, Teng CC, Inker LA, Redd A, Ying J, Woodward M, Coresh J, Levey AS. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis. 2014;64:867–79.CrossRefPubMed Greene T, Teng CC, Inker LA, Redd A, Ying J, Woodward M, Coresh J, Levey AS. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis. 2014;64:867–79.CrossRefPubMed
6.
go back to reference Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE. 2015;10:e0132927.CrossRefPubMedPubMedCentral Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE. 2015;10:e0132927.CrossRefPubMedPubMedCentral
7.
go back to reference Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.CrossRefPubMed Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.CrossRefPubMed
8.
go back to reference Matsushita K, Chen J, Sang Y, Ballew SH, Shimazaki R, Fukagawa M, Imai E, Coresh J, Hishida A. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016;90:1109–14.CrossRefPubMed Matsushita K, Chen J, Sang Y, Ballew SH, Shimazaki R, Fukagawa M, Imai E, Coresh J, Hishida A. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016;90:1109–14.CrossRefPubMed
10.
go back to reference Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed
11.
go back to reference Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36:650–4.CrossRefPubMed Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36:650–4.CrossRefPubMed
12.
go back to reference Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806–14.CrossRefPubMed Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806–14.CrossRefPubMed
13.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
14.
go back to reference Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156–63.CrossRefPubMed
16.
go back to reference Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012;27:3835–43.CrossRefPubMed Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012;27:3835–43.CrossRefPubMed
17.
go back to reference Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, Teo KK, Yusuf S, Mann JF. Acute change in glomerular filtration rate with inhibition of the renin–angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91:683–90.CrossRefPubMed Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, Teo KK, Yusuf S, Mann JF. Acute change in glomerular filtration rate with inhibition of the renin–angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91:683–90.CrossRefPubMed
18.
go back to reference Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.CrossRefPubMed Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.CrossRefPubMed
19.
go back to reference Peralta CA, Shlipak MG, Fan D, Ordoñez J, Lash JP, Chertow GM, Go AS. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006;17:2892–9.CrossRefPubMed Peralta CA, Shlipak MG, Fan D, Ordoñez J, Lash JP, Chertow GM, Go AS. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006;17:2892–9.CrossRefPubMed
20.
go back to reference Foley R, Murray A, Li S, Herzog C, McBean A, Eggers P, Collins A. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.CrossRefPubMed Foley R, Murray A, Li S, Herzog C, McBean A, Eggers P, Collins A. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.CrossRefPubMed
21.
go back to reference Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH, FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011;22:537–44.CrossRefPubMedPubMedCentral Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH, FinnDiane Study Group. Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011;22:537–44.CrossRefPubMedPubMedCentral
22.
go back to reference Rogacev KS, Bittenbring JT, Fliser D. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med. 2011;365:1745–6 (author reply 1746–7).CrossRefPubMed Rogacev KS, Bittenbring JT, Fliser D. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N Engl J Med. 2011;365:1745–6 (author reply 1746–7).CrossRefPubMed
23.
go back to reference Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2010;55:648–59.CrossRefPubMedPubMedCentral Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2010;55:648–59.CrossRefPubMedPubMedCentral
24.
go back to reference Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM. Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transplant. 2010;21:898–902. Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM. Fasting Ramadan in chronic kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transplant. 2010;21:898–902.
25.
go back to reference Melsom T, Stefansson V, Schei J, Solbu M, Jenssen T, Wilsgaard T, Eriksen BO. Association of increasing GFR with change in albuminuria in the general population. Clin J Am Soc Nephrol. 2016;11:2186–94.CrossRefPubMedPubMedCentral Melsom T, Stefansson V, Schei J, Solbu M, Jenssen T, Wilsgaard T, Eriksen BO. Association of increasing GFR with change in albuminuria in the general population. Clin J Am Soc Nephrol. 2016;11:2186–94.CrossRefPubMedPubMedCentral
Metadata
Title
Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study
Publication date
01-04-2018
Published in
Clinical and Experimental Nephrology / Issue 2/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1463-0

Other articles of this Issue 2/2018

Clinical and Experimental Nephrology 2/2018 Go to the issue